Business
Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America
SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral presentations and two posters) will be presented at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America (\"SMSNA\"), to take place October 24-27th 2019 in Nashville, TN. \n\n \nOral Presentations:\nAbstract # 271-117 LPCN 1144 Reduces Liver Fat in Men with Fatty Liver \nSession: 'Androgens' – Oral PodiumDate/time: Friday, October 25, 2019; 08:00 am - 10:00 amEstimated start time of presentation: 09:14 amTo be presented by: Irwin Goldstein, MD\nAbstract # 43-73 Improved Patient Reported Sexual and Mental Domain Outcomes with Oral Testosterone (TLANDO) Relative to Topical Testosterone in Treated Hypogonadal Men\nSession: 'Androgens - Moderated Oral Posters'Date/time: Saturday, October 26, 2019; 01:30 pm - 03:00 pmEstimated start time of presentation: 02:20 pmTo be presented by: Anthony DelConte, MD\nPosters Presentations:\nAbstract # 1013-73 Symptomatic Response to TLANDO in Patients that do not Achieve T Cavg > 300 ng/dL\nSession: E-poster Session 10 - AndrogensDate/time: Saturday, October 26, 2019; 10:05 a.m. - 10:30 a.m.Estimated start time of presentation: 10:26 amTo be presented by: Lipocine member\nAbstract # 1014-73 Paradigm Shifting Beneficial Effects of TLANDO (Oral Testosterone) on Liver\nSession: E-poster Session 2 - Basic Science / Androgens / Cancer SurvivorshipDate/time: Thursday, October 24, 2019; 03:35 pm - 04:00 pmEstimated start time of presentation: 03:56 pmTo be presented by: Lipocine member\nFurther details on these abstracts can be found on the SMSNA website.\nAbout LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs TLANDO, LPCN 1144, TLANDO XR (LPCN 1111) and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men and currently under USFDA review for marketing approval. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study d...